GlassScriptPhysician profile
Sheena M Sweeney
NPI 1619264934
$775.34
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $234 · 2021: $23.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $182.38 | 2019-2020 | |
| Allergan, INC. | $145.89 | 2019-2020 | |
| Lilly USA, LLC | $88.83 | 2019-2020 | |
| Pfizer INC. | $66.84 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $54.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $49.64 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.66 | 2019-2020 | |
| Glaxosmithkline, LLC. | $42.79 | 2019-2020 | |
| Abbott Laboratories | $42.29 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $24.29 | 2019 | |
| Sanofi Pasteur INC. | $15.68 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.70 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.